Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 15-16/2017

01.08.2017 | original article

Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients

verfasst von: Barbara Skopec, Matevz Skerget, Darja Zontar, Vesna Zadnik, Samo Zver

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2017

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

Autologous hematopoietic stem cell transplantation (aHSCT) is the recommended standard upfront treatment for transplant eligible myeloma patients. Considering possible complications related to chemotherapy–cytokine mobilization, cytokine-alone mobilization is often used. We compared mobilization with filgrastim alone to pegfilgrastim alone in newly diagnosed myeloma patients after induction treatment with bortezomib and dexamethasone. The comparison was made between peripheral blood stem cell (PBSC) yields, number of apheresis, hematopoietic stem cell subsets, and time to neutrophil and platelet engraftment after aHSCT.

Methods

A total of 42 myeloma patients were prospectively enrolled in the study: 21 received filgrastim, 21 pegfilgrastim. Flow cytometry was used to determine the number of PBSC, myeloid, lymphoid, and megakaryocyte precursors in peripheral blood and apheresis product on day 1 of apheresis.

Results

The median number of collected PBSC was 5.05 × 106/kg in the filgrastim and 4.66 × 106/kg in the pegfilgrastim group (p = 0.428). The median number of apheresis was 2.5 in the filgrastim and 2 in the pegfilgrastim group (p = 0.901). The number of megakaryocyte precursors in peripheral blood was significantly higher in the filgrastim group, but not in the apheresis products. There were no statistically significant differences in the myeloid and lymphoid precursors in the peripheral blood and in the apheresis products. The median time to neutrophil and platelet engraftment was 13 days and 16.5 days for filgrastim and 13 days and 16 days for pegfilgrastim group.

Conclusions

We can conclude that pegfilgrastim alone is at least equally successful as filgrastim alone for the PBSC mobilization in newly diagnosed myeloma patients.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
2.
Zurück zum Zitat Mohty M, Harousseau JL. Treatment of autologous stem cell eligible multiple myeloma patients: ten questions and answers. Haematologica. 2014;99(3):408–16. CrossRefPubMedPubMedCentral Mohty M, Harousseau JL. Treatment of autologous stem cell eligible multiple myeloma patients: ten questions and answers. Haematologica. 2014;99(3):408–16. CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Lonial S, Boise LH, Kaufman J. How I treat high risk myeloma. Blood. 2015;26(13):1536–43. CrossRef Lonial S, Boise LH, Kaufman J. How I treat high risk myeloma. Blood. 2015;26(13):1536–43. CrossRef
4.
Zurück zum Zitat Zver S, Mlakar U. Slovenian guidelines for the management of multiple myeloma. Zdrav Vestn. 2015;2015(84):335–51. Zver S, Mlakar U. Slovenian guidelines for the management of multiple myeloma. Zdrav Vestn. 2015;2015(84):335–51.
5.
Zurück zum Zitat Moreau P, Attal M, Facon T. Frontline therapy in multiple myeloma. Blood. 2015;125(20):3076–84. CrossRefPubMed Moreau P, Attal M, Facon T. Frontline therapy in multiple myeloma. Blood. 2015;125(20):3076–84. CrossRefPubMed
6.
Zurück zum Zitat Gertz M, Kumar S, Lacy M, et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2009;43(8):619–25. CrossRefPubMed Gertz M, Kumar S, Lacy M, et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2009;43(8):619–25. CrossRefPubMed
7.
Zurück zum Zitat Bensinger W, Di Persio JM, McCarthy JF. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant. 2009;43(3):181–95. CrossRefPubMed Bensinger W, Di Persio JM, McCarthy JF. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant. 2009;43(3):181–95. CrossRefPubMed
8.
Zurück zum Zitat To LB, Roberts MM, Haylock DN, et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant. 1992;9(4):277–84. PubMed To LB, Roberts MM, Haylock DN, et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant. 1992;9(4):277–84. PubMed
9.
Zurück zum Zitat Winkler IG, Levesque JP. Mechanisms of hematopoietic stem cell mobilization: when innate immunity assails the cells that make blood and bone. Exp Hematol. 2006;34:996–1009. CrossRefPubMed Winkler IG, Levesque JP. Mechanisms of hematopoietic stem cell mobilization: when innate immunity assails the cells that make blood and bone. Exp Hematol. 2006;34:996–1009. CrossRefPubMed
10.
Zurück zum Zitat Smith JS, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3199–212. CrossRefPubMed Smith JS, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3199–212. CrossRefPubMed
11.
Zurück zum Zitat Neupogen (filgrastim) [prescribing information]. Thousand Oaks, CA, Amgen Inc. July 2015. Neupogen (filgrastim) [prescribing information]. Thousand Oaks, CA, Amgen Inc. July 2015.
12.
Zurück zum Zitat Neulasta (pegfilgrastim) [prescribing information]. Thousand Oaks, CA, Amgen Inc. April 2016. Neulasta (pegfilgrastim) [prescribing information]. Thousand Oaks, CA, Amgen Inc. April 2016.
13.
Zurück zum Zitat Molineux G, Kinstler O, Briddell B, et al. A new form of G‑CSF with sustained duration in vivo enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol. 1999;27:1724–34. CrossRefPubMed Molineux G, Kinstler O, Briddell B, et al. A new form of G‑CSF with sustained duration in vivo enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol. 1999;27:1724–34. CrossRefPubMed
14.
Zurück zum Zitat Putkonen M, Rauhala A, Palliniemi TT, et al. Single-dose pegfilgrastim is comparable to daily filgrstim in mobilizing peripheral blood stem cells: a case matched study in patients with lymphoproliferative malignancies. Ann Hematol. 2009;88:673–80. CrossRefPubMed Putkonen M, Rauhala A, Palliniemi TT, et al. Single-dose pegfilgrastim is comparable to daily filgrstim in mobilizing peripheral blood stem cells: a case matched study in patients with lymphoproliferative malignancies. Ann Hematol. 2009;88:673–80. CrossRefPubMed
15.
Zurück zum Zitat Bruns I, Steidl U, Kronenwett R, et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD 34+ progenitors in patients with multiple myeloma. Transfusion. 2006;46(2):180–5. CrossRefPubMed Bruns I, Steidl U, Kronenwett R, et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD 34+ progenitors in patients with multiple myeloma. Transfusion. 2006;46(2):180–5. CrossRefPubMed
16.
Zurück zum Zitat Steidl U, Frenk R, Bruns I, et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G‑CSF in patients with multiple myeloma. Bone Marrow Transplant. 2005;35(1):33–6. CrossRefPubMed Steidl U, Frenk R, Bruns I, et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G‑CSF in patients with multiple myeloma. Bone Marrow Transplant. 2005;35(1):33–6. CrossRefPubMed
17.
Zurück zum Zitat Hosing C, Qazilbash MH, Kebriaei P, et al. Fix dose single agent pegfilgrastim for peripheral blood progenitor mobilization in patients with multiple myeloma. Br J Haematol. 2006;133:533–7. CrossRefPubMed Hosing C, Qazilbash MH, Kebriaei P, et al. Fix dose single agent pegfilgrastim for peripheral blood progenitor mobilization in patients with multiple myeloma. Br J Haematol. 2006;133:533–7. CrossRefPubMed
18.
Zurück zum Zitat Willis F, Wolf P, Theti D, et al. Pegfilgrastim for peripheral CD 34+ mobilization in patients with solid tumors. Bone Marrow Transplant. 2009;43(12):927–34. CrossRefPubMed Willis F, Wolf P, Theti D, et al. Pegfilgrastim for peripheral CD 34+ mobilization in patients with solid tumors. Bone Marrow Transplant. 2009;43(12):927–34. CrossRefPubMed
19.
Zurück zum Zitat Herbert KE, Gambell P, Link EK, et al. Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells. Bone Marrow Transplant. 2013;48:351–6. CrossRefPubMed Herbert KE, Gambell P, Link EK, et al. Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells. Bone Marrow Transplant. 2013;48:351–6. CrossRefPubMed
20.
Zurück zum Zitat Kamel AM, El-Sharkawy N, Mahmoud HK, et al. Impact of CD34 subsets on engraftment kinetics in allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2005;35(2):129–36. CrossRefPubMed Kamel AM, El-Sharkawy N, Mahmoud HK, et al. Impact of CD34 subsets on engraftment kinetics in allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2005;35(2):129–36. CrossRefPubMed
21.
Zurück zum Zitat Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood. 2002;99(3):731–5. CrossRefPubMed Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood. 2002;99(3):731–5. CrossRefPubMed
22.
Zurück zum Zitat Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691–5. CrossRefPubMedPubMedCentral Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691–5. CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Goldschmidt H, Hagenbart U, Haas R, et al. Mobilization of peripheral blood progenitor cells with high dose cyclophosphamide (4 or 7 mg/m2) and granulocyte colony stimulating factor in patients with multiple myeloma. Bone Marrow Transplant. 1996;17(5):691–7. PubMed Goldschmidt H, Hagenbart U, Haas R, et al. Mobilization of peripheral blood progenitor cells with high dose cyclophosphamide (4 or 7 mg/m2) and granulocyte colony stimulating factor in patients with multiple myeloma. Bone Marrow Transplant. 1996;17(5):691–7. PubMed
24.
Zurück zum Zitat Vescio R, Schiller G, Stewart AK, et al. Multicenter phase III trial to evaluate CD 34+ selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood. 1999;93(6):1858–68. PubMed Vescio R, Schiller G, Stewart AK, et al. Multicenter phase III trial to evaluate CD 34+ selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood. 1999;93(6):1858–68. PubMed
25.
Zurück zum Zitat Boccadoro M, Omedé P, Dominietto A, et al. Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support. Bone Marrow Transplant. 2000;25(1):25–9. CrossRefPubMed Boccadoro M, Omedé P, Dominietto A, et al. Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support. Bone Marrow Transplant. 2000;25(1):25–9. CrossRefPubMed
26.
Zurück zum Zitat Pozotrigo M, Adel N, Landau H, et al. Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center. Bone Marrow Transplant. 2013;48(8):1033–9. CrossRefPubMed Pozotrigo M, Adel N, Landau H, et al. Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center. Bone Marrow Transplant. 2013;48(8):1033–9. CrossRefPubMed
27.
Zurück zum Zitat Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14(9):1045–56. CrossRefPubMed Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14(9):1045–56. CrossRefPubMed
28.
Zurück zum Zitat Olivieri A, Marchetti M, Lemoli R, et al. Proposed definition of “poor mobilizer” in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo. Bone Marrow Transplant. 2012;47(3):342–51. CrossRefPubMed Olivieri A, Marchetti M, Lemoli R, et al. Proposed definition of “poor mobilizer” in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo. Bone Marrow Transplant. 2012;47(3):342–51. CrossRefPubMed
29.
Zurück zum Zitat Wolff AC, Jones RJ, Davidson NE, et al. Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. J Clin Oncol. 2006;24(15):2392–4. CrossRefPubMed Wolff AC, Jones RJ, Davidson NE, et al. Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. J Clin Oncol. 2006;24(15):2392–4. CrossRefPubMed
30.
Zurück zum Zitat Khan A, Yasin Z. Hyperleukocytosis caused by Neulasta complicated by leukostasis versus asymptomatic uncomplicated hyperleukocytosis in AML: two cases and when to leukapherese. Blood. 2013;122(21):4832. Khan A, Yasin Z. Hyperleukocytosis caused by Neulasta complicated by leukostasis versus asymptomatic uncomplicated hyperleukocytosis in AML: two cases and when to leukapherese. Blood. 2013;122(21):4832.
31.
Zurück zum Zitat Giralt S, Stadtmauer EA, Harousseau JL, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009;23(10):1904–21. CrossRefPubMed Giralt S, Stadtmauer EA, Harousseau JL, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009;23(10):1904–21. CrossRefPubMed
33.
Zurück zum Zitat Trivedi M, Martinez S, Corringham S, et al. Optimal use of G‑CSF administration after hematopoietic SCT. Bone Marrow Transplant. 2009;43(12):895–908. CrossRefPubMed Trivedi M, Martinez S, Corringham S, et al. Optimal use of G‑CSF administration after hematopoietic SCT. Bone Marrow Transplant. 2009;43(12):895–908. CrossRefPubMed
34.
Zurück zum Zitat Himmelmann B, Himmelmann A, Furrer K, et al. Late G‑CSF after allogeneic bone marrow or peripheral blood stem cell transplantation: a prospective controlled study. Bone Marrow Transplant. 2002;30(8):491–6. CrossRefPubMed Himmelmann B, Himmelmann A, Furrer K, et al. Late G‑CSF after allogeneic bone marrow or peripheral blood stem cell transplantation: a prospective controlled study. Bone Marrow Transplant. 2002;30(8):491–6. CrossRefPubMed
35.
Zurück zum Zitat Bence-Bruckler I, Bredeson C, Atkins H, et al. A randomized trial of granulocyte colony stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant. 1998;22(10):965–9. CrossRefPubMed Bence-Bruckler I, Bredeson C, Atkins H, et al. A randomized trial of granulocyte colony stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant. 1998;22(10):965–9. CrossRefPubMed
36.
Zurück zum Zitat Fruehauf S, Tricot G. Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplantation outcomes. Biol Bone Marrow Transpl. 2010;16(12):1629–48. CrossRef Fruehauf S, Tricot G. Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplantation outcomes. Biol Bone Marrow Transpl. 2010;16(12):1629–48. CrossRef
37.
Zurück zum Zitat Donzella GA, Schols D, Lin SW, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med. 1998;4(1):72–7. CrossRefPubMed Donzella GA, Schols D, Lin SW, et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med. 1998;4(1):72–7. CrossRefPubMed
38.
Zurück zum Zitat Varmavuo V, Mantymaa P, Silvennoinen R, et al. CD34+ subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients. Transfusion. 2013;53(5):1024–32. CrossRefPubMed Varmavuo V, Mantymaa P, Silvennoinen R, et al. CD34+ subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients. Transfusion. 2013;53(5):1024–32. CrossRefPubMed
Metadaten
Titel
Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients
verfasst von
Barbara Skopec
Matevz Skerget
Darja Zontar
Vesna Zadnik
Samo Zver
Publikationsdatum
01.08.2017
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 15-16/2017
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-017-1205-z